Milad Khan

Milad Khan is an experienced professional in regulatory affairs and drug development, currently serving as an External Consultant at RApport Global Strategic Services, focusing on early oncology drug development and an established marketed product since June 2021. Milad has held various significant roles including Director of Regulatory Affairs at Purdue Pharma L.P., where responsibilities encompassed primary regulatory contact with the FDA and supporting therapeutic areas such as Oncology, CNS, Addiction, and Pain Medicines. Prior positions include Associate Director at Taiho Oncology, Inc., Manager at The Janssen Pharmaceutical Companies of Johnson & Johnson, and Director of Regulatory Affairs at Huahai US, Inc. Milad's early career includes roles in research and formulation at Merial and Baxter International, enhancing a strong foundation in drug development. Educational qualifications include an MS in Drug Regulatory Affairs from Long Island University, a QA/RA certification from Temple University, and a B. Pharm and M. Pharm from Dhaka University.